ClinicalTrials.gg
RecruitingNCT07421674Updated Nov 17, 2026

Assessing Hydromorphone Sustained-Release Tablets in Elderly Cancer Pain Patients With Renal Insufficiency

An observational study in Cancer Pain, Renal Insufficiency Chronic and Hydromorphone Use, sponsored by Taian Cancer Hospital. Recruiting at 1 site in China. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Taian Cancer Hospital · Observational

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Nov 17, 2026Now RecruitingSite recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
62
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Cancer Pain with a site in China — 13 open to participants now, 13 under way, 1 of them phase 3. Cancer Pain · China.

Started
2026
with 4 others
Observational
7 of 31
6 open now
Primary completion
2028-12
later than 11 of 12 live
Registered
26th of 31
by date

Among the 31 studies in Cancer Pain with a site in China, this one is one of 5 that started in 2026, is one of 7 observational ones, reaches primary completion later than 11 of the 12 other live ones, and was the 26th registered.

Cancer Pain

311 studies on the registry are indexed under Cancer Pain; 74 are open to participants now.

Browse Cancer Pain studies →

Open to participants now

13 of the 31 studies in Cancer Pain with a site in China are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 45 Cancer Pain studies recruiting now, 33 (73%) set no upper age limit and 4 (9%) stop at 75 or younger; 4 take children under 18; none take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Cancer Pain with a site in China, or all of them as a file.
02

Study summary

This clinical study aims to understand whether domestic hydromorphinone sustained-release tablets are effective and safe in treating moderate to severe cancer pain in elderly patients with renal insufficiency.

It will also understand key safety concerns, especially regarding renal function and neurotoxicity.

The main questions it aims to answer include:1. Can hydromorphinone sustained-release tablets effectively relieve the pain of such patients and improve their quality of life?2. During the treatment period, what effect does this drug have on renal function (measured by eGFR)? 3. In this specific population, what are the occurrence and characteristics of neurotoxicity and other side effects induced by opioids? Researchers will compare elderly cancer pain patients with renal insufficiency with those with normal renal function (both receiving the study drug treatment) to observe whether there are differences in efficacy and safety results.

Participants will:

Receive a standardized treatment plan: First, subcutaneous injection of hydromorphinone injection for dose titration, and then switch to daily oral administration of hydromorphinone sustained-release tablets for 4 weeks.

Visit the clinic for assessment and examination (including renal function tests) during the baseline period, on the 7th day, and at the weekends of the 2nd, 3rd, and 4th days.

Regularly monitor and record the degree of pain, the occurrence of explosive pain, the use of medication, and any side effects.

Read the detailed description
  1. The research background and principle of elderly cancer patients are often faced with moderately severe pain, the pain management is particularly complex in this group. The physiological functions of the elderly decline, often accompanied by a decrease in renal function, which significantly limits the safe use of many standard opioid analgesics, such as morphine. The active metabolites of morphine tend to accumulate in patients with renal insufficiency, increasing the risk of neurotoxicity. Another commonly used drug, oxycodone, may cause a relatively high incidence of gastrointestinal adverse reactions. Hydromorphinone is a potent opioid drug, and its pharmacological properties may offer a solution to this predicament. It is mainly metabolized through liver glucoaldehyde acidification, generating inactive metabolites, and does not rely on the complex cytochrome P450 enzyme system. Therefore, the risk of drug interactions is relatively low, and theoretically, it has a smaller impact on kidney function, especially suitable for elderly patients with reduced kidney function. However, although there have been some studies on imported hydromoradone preparations, domestic hydromoradone hydrochloride sustained-release tablets (such as Ruining ®) have lacked prospective and systematic clinical evidence in the cancer pain population characterized by dual risk factors of "old age" and "renal insufficiency" since their launch. This study aims to fill this crucial gap in evidence.
  2. The research design and methodology described in this study using prospective, observational cohort design. Unlike randomized controlled trials, this study aims to observe the natural outcomes of standardized treatment regimens in elderly patients with different renal function statuses under real-world conditions. All eligible patients enrolled in the group will receive a unified analgesic treatment plan based on international authoritative guidelines: Firstly, subcutaneous injection titration of hydromorphinone injection will be performed to quickly determine the individualized dose required for pain control; After the pain stabilized, it was uniformly converted to the same dose of domestic hydromorphinone sustained-release tablets for oral maintenance treatment once daily. The total treatment observation period was 4 weeks.

    The key to the research lies in "hierarchical comparison". Before treatment, the investigators will naturally divide the patients into two cohorts based on their estimated glomerular filtration rate (eGFR, a core indicator for evaluating renal function) : the "Elderly with renal insufficiency group" and the "Elderly with normal renal function Group". In this way, the investigators can directly compare the performance differences of the drug in these two types of people with different physiological states.

    The sample size calculation (planned to include a total of 62 patients) was based on the primary safety endpoint - the change in eGFR values relative to baseline at week 4 of treatment. A clinically significant effect size was preset during the calculation, and sufficient statistical certainty was ensured to guarantee the reliability of the research results.

  3. The core assessment and monitoring framework in addition to conventional pain intensity assessment (NRS) adopting digital grading method, quality of living survey and common adverse reactions, this research established dual core security monitoring system:

    Dynamic monitoring of renal function: Serum creatinine will be systematically detected and eGFR calculated at five time points before and during treatment. This is not only used to compare the differences between groups, but more importantly, to monitor the dynamic trajectory of each patient's individual renal function and promptly detect any clinically significant signs of deterioration.

    Active screening for neurotoxicity (OIN) : In response to neurotoxic symptoms such as delirium, drowsiness, and myoclonus that may be caused by opioids, the study will conduct active screening and assessment once a week using a series of standardized scales, for example, using the Confusion Assessment method (CAM) to screen for delirium. This systematic monitoring aims to capture the incidence and characteristics of OIN more precisely.

  4. Data analysis, statistical analysis strategy will use advanced statistical models to cope with the complexity of clinical data. For the primary endpoint (eGFR change), covariance analysis will be used to correct for baseline eGFR differences during statistical analysis, thereby more purer assessing the impact of the treatment itself on renal function. For data such as pain scores that are repeatedly measured at different time points, generalized estimating equations will be used for analysis to effectively utilize all the information of the longitudinal data. Furthermore, if a sufficient number of neurotoxic events are observed in the study, the investigators will conduct an exploratory analysis and attempt to construct a clinical risk prediction tool (nomogram) using a multi-factor regression model to identify high-risk patients with OIN.
  5. The risk control and clinical patient safety is the primary consideration. The research protocol is equipped with clear safety suspension rules: once a patient's eGFR drops by more than 30% from baseline or falls within the range of severe renal failure, the study medication will be immediately suspended and a multidisciplinary consultation will be initiated. For patients with moderate to severe neurotoxicity, there are already pre-established alternative analgesic regimens (such as switching to fentanyl transdermal patches). The entire research was carried out on the "Standardized Cancer Pain Treatment Demonstration Ward" platform of Tai 'an Cancer Hospital. This team has mature cancer pain management and emergency response procedures.
  6. The value of the research and production in this study beyond the simple answer of "analgesia is effective", focus on "in the vulnerable groups is safe" more pressing clinical problem. Its achievements are expected to provide value on three levels:

Direct evidence: It provides the first prospective efficacy and safety data for the application of domestic hydromoradone sustained-release tablets in elderly patients with renal insufficiency.

Clinical guidance: Clarify the adverse reaction spectrum of this drug in this population, especially its specific effects on renal function and the nervous system, to provide a basis for clinical dose adjustment and risk early warning.

Methodological demonstration: Demonstrate how to answer practical questions about medication safety for specific high-risk populations through rigorous observational studies and advanced statistical methods.

Through this research, the investigators hope to provide decision support based on localized drugs and high-level evidence for clinicians when treating this complex and vulnerable patient group, ultimately promoting the precision and safety improvement of cancer pain management in the elderly.

03

Conditions studied

  • Cancer Pain
  • Renal Insufficiency Chronic
  • Hydromorphone Use

Keywords

  • Cancer Pain
  • Renal Insufficiency
  • Aged
  • Hydromorphone
  • Opioid-Induced Neurotoxicity
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Study participants will be selected from the patient population presenting at the Oncology Department of Taian City Tumor Hospital, a regional tertiary cancer care center in Shandong Province, China. Recruitment will specifically target older adult patients with cancer who are being evaluated for and initiate standardized opioid therapy for moderate-to-severe cancer pain at this institution.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 65 years.
  2. or cytologically confirmed malignant tumor.
  3. Opioid-naïve patients with moderate-to-severe cancer pain (Numerical Rating Scale score ≥ 4).
  4. Renal function meeting one of the following criteria at baseline:

1)Mild-to-moderate renal insufficiency group: 30 mL/min/1.73m² ≤ estimated (eGFR) \< 90 mL/min/1.73m².

2)Normal renal function group: eGFR ≥ 90 mL/min/1.73m². 5.Expected survival period ≥ 3 months. 6.Ability to take oral medication and cooperate with study assessments. 7.Willing to participate voluntarily and able to provide signed .

Exclusion criteria

Exclusion Criteria:

  1. Severe renal insufficiency ( \< 30 mL/min/1.73m²) or requirement for renal replacement therapy.
  2. Severe hepatic insufficiency ( / aspartate aminotransferase ≥ 2.5 times the or Class C).
  3. Paralytic ileus.
  4. Pain of unclear origin or pain that is solely acute/incident pain.
  5. Symptoms or history of diseases such as intracranial hypertension, head injury, cerebral aneurysm, or other central nervous system disorders.
  6. Symptoms of prostatic hypertrophy, thyroid dysfunction, or urethral stricture. Symptoms of asthma, respiratory obstruction, or respiratory failure.
  7. Known allergy or to hydromorphone or oxycodone.
  8. Use of monoamine oxidase inhibitors within 14 days prior to enrollment.
  9. Participation in any other clinical trial within 1 month prior to enrollment.
  10. Any other condition considered by the investigator as unsuitable for participation in this study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
62 participants (estimated)
Target follow-up
4 Weeks
Patient registry
Yes

Groups and cohorts

  • Hydromorphone - Renal Insufficiency Group

    Elder cancer pain patients with mild to moderate renal insufficiency at enrollment, defined by an estimated glomerular filtration rate (eGFR) range of 30 ≤ eGFR \< 90 mL/min/1.73m². They receive standardized Hydromorphone Sustained-Release Tablet treatment.

  • Hydromorphone - Normal Renal Function Group

    Elder cancer pain patients with normal renal function at enrollment, defined by an estimated glomerular filtration rate (eGFR) of eGFR ≥ 90 mL/min/1.73m². They receive the identical standardized Hydromorphone Sustained-Release Tablet treatment as Cohort 1, serving as the reference comparison group.

06

What researchers measure

Primary outcomes

  1. The changes in estimated glomerular filtration rate (eGFR) from baseline at the end of the 4th week of treatmentDetailed

    The estimated glomerular filtration rate (eGFR) is a validated indicator of kidney function. It is calculated from serum creatinine using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, which incorporates the patient's age and sex. All values are normalized to body surface area and expressed as mL/min/1.73m². On this scale, higher eGFR values indicate better kidney function, while lower values indicate impaired kidney function. The change in eGFR is defined as the value measured at week 4 minus the value measured at baseline (immediately prior to treatment initiation). A negative change value indicates a decrease in eGFR from baseline, representing a decline in kidney function. A positive change value indicates an increase in eGFR from baseline, representing an improvement in kidney function. eGFR is measured from venous blood samples collected at baseline and at week 4.

    Time frame: From the start of maintenance treatment with hydromorphinone sustained-release tablets until the end of the fourth week of treatment.

07

Study locations

1 of 1 sites recruiting
  • Tai'an Caner Hospital
    Tai’an, Shandong 271000, China
    Recruiting
    • Xiaomei He · Contactyifanmami@126.com · +86 13705383066
    • Junjun Hou · Principal investigator
    • Lijin Ren · Sub investigator
    • Jijie Shi · Sub investigator
    • Yueqian Cui · Sub investigator
    • Ning Tian · Sub investigator
    • Juan Wang · Sub investigator
08

References and documents

Publications

  • Zheng MD, Li YX, Wang ZY, Ma H, Wang Y, Qiao TT, Krasovitsky MS, Tatar C, Karlekar M, Yan J. Patient-controlled analgesia with hydromorphone treatment for advanced colon cancer with severe pain in an older adult patient: a case report and literature review. J Gastrointest Oncol. 2024 Oct 31;15(5):2330-2337. doi: 10.21037/jgo-24-713. Epub 2024 Oct 29. PubMed 39554558 ↗
  • Lin R, Lin S, Feng S, Wu Q, Fu J, Wang F, Li H, Li X, Zhang G, Yao Y, Xin M, Lai T, Lv X, Chen Y, Yang S, Lin Y, Hong L, Cai Z, Wang J, Lin G, Lin S, Zhao S, Zhu J, Huang C. Comparing Patient-Controlled Analgesia Versus Non-PCA Hydromorphone Titration for Severe Cancer Pain: A Randomized Phase III Trial. J Natl Compr Canc Netw. 2021 Aug 3;19(10):1148-1155. doi: 10.6004/jnccn.2020.7699. PubMed 34343968 ↗
  • Hanna M, Thipphawong J; 118 Study Group. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliat Care. 2008 Oct 31;7:17. doi: 10.1186/1472-684X-7-17. PubMed 18976472 ↗
  • van Ojik AL, Jansen PA, Brouwers JR, van Roon EN. Treatment of chronic pain in older people: evidence-based choice of strong-acting opioids. Drugs Aging. 2012 Aug 1;29(8):615-25. doi: 10.2165/11632620-000000000-00000. PubMed 22765848 ↗
  • Kullgren J, Le V, Wheeler W. Incidence of hydromorphone-induced neuroexcitation in hospice patients. J Palliat Med. 2013 Oct;16(10):1205-9. doi: 10.1089/jpm.2012.0467. Epub 2013 Aug 9. PubMed 23930920 ↗
  • Carter NJ, Keating GM. OROS hydromorphone prolonged release: a review of its use in the management of chronic, moderate to severe pain. CNS Drugs. 2010 Apr;24(4):337-61. doi: 10.2165/11202580-000000000-00000. PubMed 20297858 ↗
  • Odoma VA, Pitliya A, AlEdani E, Bhangu J, Javed K, Manshahia PK, Nahar S, Kanda S, Chatha U, Mohammed L. Opioid Prescription in Patients With Chronic Kidney Disease: A Systematic Review of Comparing Safety and Efficacy of Opioid Use in Chronic Kidney Disease Patients. Cureus. 2023 Sep 18;15(9):e45485. doi: 10.7759/cureus.45485. eCollection 2023 Sep. PubMed 37727840 ↗
  • Liu L, Xu M, Wang J, Hu Y, Huang Z. Research Progress of Hydromorphone in Clinical Application. Physiol Res. 2025 Mar 21;74(1):41-48. doi: 10.33549/physiolres.935354. PubMed 40116549 ↗
  • Lim KH, Nguyen NN, Qian Y, Williams JL, Lui DD, Bruera E, Yennurajalingam S. Frequency, Outcomes, and Associated Factors for Opioid-Induced Neurotoxicity in Patients with Advanced Cancer Receiving Opioids in Inpatient Palliative Care. J Palliat Med. 2018 Dec;21(12):1698-1704. doi: 10.1089/jpm.2018.0169. Epub 2018 Sep 27. PubMed 30260731 ↗
  • Kim YS, Kim WY. Reversible decorrelation method for progressive transmission of 3-D medical image. IEEE Trans Med Imaging. 1998 Jun;17(3):383-94. doi: 10.1109/42.712128. PubMed 9735902 ↗
  • Owsiany MT, Hawley CE, Triantafylidis LK, Paik JM. Opioid Management in Older Adults with Chronic Kidney Disease: A Review. Am J Med. 2019 Dec;132(12):1386-1393. doi: 10.1016/j.amjmed.2019.06.014. Epub 2019 Jul 8. PubMed 31295441 ↗
  • Kimmel PL, Fwu CW, Abbott KC, Eggers AW, Kline PP, Eggers PW. Opioid Prescription, Morbidity, and Mortality in United States Dialysis Patients. J Am Soc Nephrol. 2017 Dec;28(12):3658-3670. doi: 10.1681/ASN.2017010098. Epub 2017 Sep 21. PubMed 28935654 ↗
  • Roy PJ, Weltman M, Dember LM, Liebschutz J, Jhamb M; HOPE Consortium. Pain management in patients with chronic kidney disease and end-stage kidney disease. Curr Opin Nephrol Hypertens. 2020 Nov;29(6):671-680. doi: 10.1097/MNH.0000000000000646. PubMed 32941189 ↗
  • Mullins S, Hosseini F, Gibson W, Thake M. Physiological changes from ageing regarding pain perception and its impact on pain management for older adults. Clin Med (Lond). 2022 Jul;22(4):307-310. doi: 10.7861/clinmed.22.4.phys. PubMed 35882493 ↗
  • Domenichiello AF, Ramsden CE. The silent epidemic of chronic pain in older adults. Prog Neuropsychopharmacol Biol Psychiatry. 2019 Jul 13;93:284-290. doi: 10.1016/j.pnpbp.2019.04.006. Epub 2019 Apr 17. PubMed 31004724 ↗
  • van den Beuken-van Everdingen MH, Hochstenbach LM, Joosten EA, Tjan-Heijnen VC, Janssen DJ. Update on Prevalence of Pain in Patients With Cancer: Systematic Review and Meta-Analysis. J Pain Symptom Manage. 2016 Jun;51(6):1070-1090.e9. doi: 10.1016/j.jpainsymman.2015.12.340. Epub 2016 Apr 23. PubMed 27112310 ↗
  • Pysz-Waberski DT, Sadurska J, Kedzierska-Jamroz J, Pietrzynski L, Lorek A, Jarosz M, Gisterek I. Multidisciplinary management of chronic pain in elderly oncology patients. Contemp Oncol (Pozn). 2022;26(3):157-164. doi: 10.5114/wo.2022.119466. Epub 2022 Sep 22. PubMed 36381668 ↗
  • Swarm RA, Youngwerth JM, Agne JL, Anitescu M, Are M, Buga S, Butler T, Chwistek M, Cleary J, Copenhaver D, Coyne C, Craig D, Finnes H, Greenlee H, Gupta M, Hansen E, Javed S, Kandil E, Mackey S, McDonald A, McGrath K, Moryl N, Nesbit S, Noonan M, Norris J, Paice JA, Prsic E, Rabow MW, Rickerson E, Sindt J, Smith M, Vorenkamp K, Bruce JY, Yoo S, Cunningham R, Gurski LA, Jones F. Adult Cancer Pain, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025 Jul;23(7):e250032. doi: 10.6004/jnccn.2025.0032. PubMed 40639401 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual participant data that underlie the results reported in the primary publication (including demographics, baseline clinical characteristics, serial eGFR measurements, pain scores, and safety outcomes) will be shared. Supporting documents like the study protocol and statistical analysis plan will also be provided. Data will become available 12 months after article publication to researchers who submit a methodologically sound proposal and sign a data use agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Start Date :12 months after the publication of the primary study results in a peer-reviewed journal. End Date : 5 years after the IPD sharing start date.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Dec 2028, 34 months after the start.

Of 26 observational studies under Cancer Pain, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 40. This study's planned 34 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2026
First posted
Feb 19, 2026
StartActual
Feb 10, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 17, 2026
Sites
Tai'an Caner Hospital is now Recruiting
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Not yet recruiting→Recruiting
    Tai'an Caner Hospital is now Recruiting
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07421674
Lead sponsor
Taian Cancer Hospital
Responsible party
Xian'guo Wang (Chief Physician, Taian Cancer Hospital) — Principal investigator
First posted
Feb 19, 2026
Start date
Feb 10, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

Xian'guo Wang
Contact
wangxianguo1111@163.com
+8613562898761
Junjun Hou
Contact
+8613583834178

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion